Search
Ivacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigational[L6841] Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF. … Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals.
Selexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalSelexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169] … [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.
Categories: Agents for Dermatitis, Excluding CorticosteroidsOlezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia. … Olezarsen is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (APOC3, apoC-III),[L52033] which is a key regulator of triglyceride levels in plasma, in the liver
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaPramipexole
go.drugbank.com/drugs/DB00413ApprovedInvestigationalIn addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873].
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawn[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesEmpagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. … [A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).
Ditiocarb zinc
go.drugbank.com/drugs/DB14193ApprovedDitiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen.
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UsePidolic acid
go.drugbank.com/drugs/DB03088ApprovedInvestigationalThere are currently little to no medicines available that are clinically approved or marketed for employing pidolic acid as an active ingredient for any particular formal indication. … Although pidolic acid is included in some over-the-counter, non-prescription dietary supplements for the proposed purpose of facilitating cognitive or memory enhancement, most available research suggest
Factor IX Complex (Human)
go.drugbank.com/drugs/DB11330ApprovedInvestigationalAlthough Factor IX Complex products contain many different coagulation components, Factor IX is the lead component for potency and efficacy, particularly when used for the treatment of bleeding associated … For example, Kcentra (FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) contains heparin.